Profound Medical Corp. (PRN) Earnings Call Transcript & Summary
November 5, 2026
Earnings Call Speaker Segments
Stephen Kilmer
executiveThanks, operator, and good afternoon to all of you. I'd like to welcome everyone to Profound Medical's conference call for the third quarter of 2026. First, let me note that this call will contain forward-looking statements as defined under the securities laws that apply in both the United States and Canada. Every forward-looking statement rests on Profound's present beliefs, assumptions and expectations and touches on matters including, among other things, our current or future financial performance and position, the outlook for revenue and gross margin, commercialization activities, customer utilization, product development, leadership succession, and expectations about how effective our technologies will be. Such statements carry known and unknown risks, uncertainties and other factors that could cause actual results, performance or achievements to differ materially from those expressed or implied. There is no guarantee behind any forward-looking statement. We caution listeners against placing undue reliance on these statements, since they speak only as of today. We encourage you to review the risk factors set out in our filings with the U.S. and Canadian securities regulators. Except where the law requires it, Profound assumes no obligation to publicly update or revise forward-looking statements. With us today are Dr. Arun Menawat, our Chief Executive Officer and Chairman; Matthew Sobczyk, our Chief Financial Officer; Tom Tamberrino, Chief Commercial Officer; Mathieu Burtnyk, our Chief Technology Officer; and Richard Fabian, our current President and incoming CEO. There's a lot on the agenda today. Matthew will start with the financial results, then Rich will cover operational priorities and Tom will address commercial progress. After that, Arun will give a strategic update before we take questions. One quick heads-up on that front: Arun is still recovering from a bad cold, so his voice may cut in and out from time to time. With that, I'll hand the call over to Matthew.
Matthew Sobczyk
executiveGood afternoon, everyone. On behalf of the management team and all of us at Profound, thank you for your ongoing interest and support. Before I hand the call to Rich for an operational update, I'll take a brief moment to go over our financial results for the third quarter of 2026. During the 3 months that ended September 30, 2026, Profound posted total revenue of $9.8 million, which represents an 86% increase over the third quarter of 2025. That revenue was made up of $4.1 million in recurring noncapital revenue from single-use devices and service tied to extended warranties, plus $5.7 million in capital equipment sales. Gross margin reached 78%, compared with 74% during the same quarter last year, helped by a product mix that worked in our favor and by pricing discipline that stayed strong. Operating expenses were $15.5 million in total, a 21% rise year-over-year. The growth was mostly due to more staff, bigger commission costs tied to our revenue growth, travel spending, and increased consulting spending linked to R&D work meant to lower product costs and boost efficiency. Partly balancing those were reduced clinical trial costs, which came from finishing enrollment in the CAPTAIN trial. Our net loss narrowed 3% to roughly $7.7 million, or $0.21 per common share, against roughly $8 million, or $0.26 per common share, in the third quarter of 2025. Operating activities consumed $5 million in cash. That represents a 56% sequential decline from $11.3 million during the second quarter of 2026, and a 48% drop relative to $9.6 million in last year's third quarter. We closed September holding roughly $33.3 million in cash. Today, 36,626,844 common shares stand outstanding. Taking into account results through September plus our outlook for the remainder of the year, we anticipate 2026 full-year revenue of no less than $25 million, with gross margin at 70% or above. As highlighted in today's press release, we believe current cash alongside revenue generated from product and service sales will cover our operating and capital expenditure needs for a minimum of the coming 12 months. Although we aren't planning to raise capital right away, we'll keep an eye out for chances to secure funding—whether through dilutive or nondilutive means—that help us reach profitability, weighing what the business requires against how much shareholder dilution we're willing to accept. Our priorities for allocating capital involve backing commercial execution, boosting efficiency, and reinforcing the operational capabilities the company will need as it expands. We'll keep measuring those investments against the financial means we have and our aim of creating a business that grows profitably. With that said, I'll hand things over to Rich.
Richard Fabian
executiveThank you, Matthew, and good afternoon to all of you. I value the trust that Arun and the Board have shown in me. It's my privilege to take on the CEO role at Profound and to collaborate with Arun as Executive Chairman starting in mid-January. Arun contributed enormously by steering TULSA-PRO through FDA clearance and CMS reimbursement and onward into commercial adoption. Our platform rests on a solid clinical evidence foundation, a commercial opportunity that keeps expanding, and the capacity to produce recurring revenue whenever customers carry out procedures. My main goal is to grow this organization and help turn that into dependable execution. First, we must turn our commercial pipeline into placements; this calls for rigorous opportunity management, transparent customer economics, and tight coordination among sales, installation, and support. Cook Medical represents another important channel, and we must ensure that relationship delivers results alongside our own direct sales efforts. Second, we have to assist customers in raising utilization. Every extra productive system opens the door to more recurring revenue and makes our business economics stronger. A placement marks the start of a customer relationship, and the effort that comes afterward matters greatly. We concentrate on the practical side of a successful program: physician engagement, training, scheduling, referral development, and coordination inside the facility, with support ready whenever customers need it, especially when they first start treating patients. Third, we must boost operating efficiencies as we grow. Our engineering spending targets TULSA Procedures that are better and faster, while also opening chances to keep cutting costs further down the road. As we prepare for 2027, we will weigh added investment in utilization support and program start-up with financial discipline and explicit performance expectations. I also believe there is value in deepening our ties throughout the imaging and physician communities. Interventional MRI forms a key element of Profound's strategy. Our near-term job is to make TULSA programs succeed for customers now, while building capabilities that could extend the platform's value later on. The third quarter gives us an encouraging base: higher revenue, a strong gross margin, and lower operating cash use. We aim to extend that progress and steer Profound toward growth that is sustainable and profitable. I'm now glad to hand the call to Tom.
Thomas Tamberrino
executiveThanks, Rich, and good afternoon. As Rich just mentioned, our commercial priorities involve turning qualified opportunities into placements and assisting every installed customer in building a productive TULSA program. By the close of the third quarter, our installed base for TULSA-PRO stood at 98 systems. We have also just hit a significant milestone for utilization of existing systems, with the 5,000th TULSA Procedure carried out in October. Our qualified sales pipeline for TULSA-PRO and Sonalleve came to roughly $79.2 million at the end of the quarter. Consistent with prior calls, qualified opportunities are those at the verify, negotiate, or contracting stages. Our pipeline is a gauge of potential opportunity, and we can't guarantee how much of it will turn into recognized revenue or when that might happen. As Rich mentioned, we've brought on an important new distribution channel for TULSA products via a supply and distribution agreement inked last week with Cook Medical, one of the biggest privately held medical device makers in the United States. The way it's structured is significant: Cook will purchase TULSA-PRO systems at a transfer price set in advance. When customers buy systems via Cook, Profound will supply the disposables and service contracts straight to them. That fits well with what our sales team keeps concentrating on: selling TULSA-PRO for the 1.5 Tesla and 3 Tesla MRI machines already in place, which the agreement doesn't cover. It also lets us keep direct ties with U.S. customers for disposables and service, no matter how they get their TULSA-PRO systems. Cook's interventional MRI work gives us a strong base for the launch ahead. Some of you likely know that Cook ranks among the biggest makers of MR-compatible biopsy systems and needles, among other things. So the deal lines up neatly with our belief that iMRI settings built for the purpose can widen access to image-guided procedures. We'll keep investors informed through separate updates on product integration and regulatory milestones when it makes sense to do so. Another essential element in getting a system to be productive is payer coverage. On that front, Profound kept making meaningful strides in engaging commercial payers for the TULSA procedure. During the third quarter of 2026 by itself, about 10.7 million covered lives were added via commercial and government payers. Roughly 1.8 million of those came through commercial and Medicare Advantage programs. Naturally, having coverage on its own doesn't guarantee utilization. Programs also require clear referral pathways, coordinated scheduling and efficient workflows. Our efforts with payers and providers center on broadening coverage in areas where it's required and assisting customers with patient access navigation; we see a significant growth opportunity ahead; and, as Rich mentioned, we'll put more investment into our customer support teams as the installed base expands. Our aim is to assist customers in moving more efficiently from installation to initial procedures and afterward to a sustainable treatment schedule. We'll keep using clinical education to support adoption as well. The expanding evidence base, the recent symposium presentations, and our co-education partnership with Telix open up opportunities to engage physicians regarding treatment planning and the clinical role of TULSA. In summary, the commercial opportunity is considerable. The team is concentrating on turning interest into customer decisions and assisting those customers in treating patients consistently. At this point, I'll hand the call over to Arun.
Arun Menawat
executiveThank you, Tom, and good afternoon to all of you. Our company is changing quickly at present. In our view, barriers to transformation are falling, and a meaningful chance to expand is right in front of us. It's an honor and a pleasure that Rich has come aboard to steer the coming stage of growth, and on behalf of the company's Board I extend him a welcome. Rich, Tom and Matthew already form a AAA level team and give us strong confidence in what lies ahead for Profound. My presentation today runs a little longer than usual. Prostate care's market is in motion, and we think we're well placed for what comes next in this period of change. Let me start by explaining the technical and financial foundations of our business, and then I'll go through what the fresh industry deals we've inked might deliver in terms of their capacity to add to our growth. Looking at the big picture, we think the competitive environment continues to work in Profound's favor. Newer technologies are drawing interest toward choices that go past the longer-standing therapies, and that creates a chance for TULSA. We also notice fresh entrants in robotics, including J&J and Medtronic, devoting considerable funding to this space; from our vantage point, it remains premature to judge how they will distinguish themselves versus Intuitive, yet we believe clinical differentiation along with capital efficiency will ultimately matter more than the size of a development budget. Let me start by explaining why we believe TULSA is securing its role within standard prostate treatment. Our pitch starts with MRI accuracy, thorough imaging of the tumor and its margins, live temperature monitoring, and the ability to assess the therapy administered once the procedure concludes. As we see it, ultrasound imaging doesn't offer comparable visualization of cancer edges, and today's robotics don't deliver sufficient precision. That hands TULSA physicians a key advantage when planning and controlling ablation with pixel-by-pixel accuracy. The energy source matters too. Our view is that TULSA delivers the gentlest energy among these approaches, since we heat tissue only to the temperatures required for cell death. According to our internal technical comparisons, TULSA typically uses roughly 1/10 the energy of HIFU and 1/100 the energy of histotripsy technology to kill tissue. The question we raise about higher-energy approaches is where that extra energy ends up and what potential there is to harm surrounding tissue. Based on what we've seen internally, doctors are more and more aware of what competing technologies can't do, and that awareness is helping them see, by comparison, the clinical benefit of TULSA's controlled delivery of energy. TULSA gets MR feedback and modifies energy as treatment goes on, while active cooling keeps the urethra and the rectum protected the whole time. That adaptability is central to how we position the product. A physician can choose TULSA for whole-gland ablation, for focal ablation, or for any option in between; we refer to that as regional ablation, since the treatment can be tailored to the clinical situation across that spectrum. The utilization figures for the third quarter in today's release demonstrate that breadth. Looking at how procedures break down, whole-gland treatment makes up 42%, sub-total comes in at 24%, hemi-gland ablation is 22%, and focal therapy represents 12%. Doctors used TULSA across a range of prostate conditions and gland sizes as well. Cases included prostate cancer alone, men with both prostate cancer and BPH, recurring malignant tissue, and BPH on its own; that track record reinforces our belief that the platform's flexibility is a key factor behind physicians' decision to invest in building a TULSA program. All told, the total available market, or TAM, for TULSA in the United States by itself is 600,000 patients annually, which means it exceeds the TAM of competing technologies. Clinical publications keep showing that our technology can treat a broad range of patients, and they provide solid backing for TULSA's TAM. As we noted during the second quarter call, CAPTAIN achieved its primary safety endpoint, demonstrating statistically superior preservation of the combined measure of urinary continence and erectile function at 6 months relative to robotic radical prostatectomy. Further results presented in July demonstrated statistically superior preservation of flaccid penile length after whole-gland TULSA; so honestly, TULSA already leads on the clinical front; yet for me, the key finding was that a TULSA patient returns to 90% of his baseline condition within 24 hours of the procedure, whereas robotic prostatectomy patients need 14 days to reach that point. TULSA isn't just about avoiding a hospital stay — it's also about recovering quickly, and that translates into real money for a lot of patients. Going forward, our plan is to release the one-year CAPTAIN results, covering recurrence and side effects, at RSNA in early December. As the meeting gets closer, we'll share further specifics. Now I'd like to go over two agreements we've signed in the recent past. The first is Profound, which enables diagnostic-grade imaging — providing physicians with a dependable, clear view of the disease anatomy so they can plan treatment with precision. Urologists get it—this new era of surgery without incisions demands accuracy in imaging, and they're keen to learn how combining the precision of MR with PSMA-PET can enhance patient care. Telix's sales force is at least ten times the size of ours, and as a pharma company they bring considerable educational firepower. The mutual benefit is that they supply the educational resources while TULSA supplies the clinical rationale. Pairing MR with PSMA imaging gives the finest imaging platform available, hands down, letting surgeons plan procedures with maximum precision. In addition to our physician education work with Telix, we take pride in the Profound-sponsored Let's Huddle effort aimed at patient education. We completely filled all spots for the live Stretch education event held earlier today, and it was a privilege to have Montel Williams and Leonard Wheeler serve as its leaders. A second deal we recently finalized involves the new iMRI division at Cook Medical. Employing MR within intervention is no longer viewed as the boogeyman it once was. Our relationships with Siemens and Cook make it clear that larger corporations are now investing money to build and install iMRI suites in hospitals. I want to honor Peter Polverini, Vice President and Leader of Cook's iMRI division, for his dedication to what we refer to as the TULSA+ program, under which his division will offer users a turnkey package combining MRI and TULSA. In our view, this arrangement will deliver substantial expansion in TULSA adoption. What urologists tell us is that every one of them wants an iMRI of their own so they have the flexibility to schedule interventions. As you're aware, TULSA HOPD reimbursement already exceeds that of every other technology employed in treating prostate cancer, and that gives a compelling financial rationale for buying a new TULSA+ iMRI suite. Meanwhile, our reps will continue marketing TULSA-PRO directly to the existing pool of diagnostic-grade MRI installations. Let me restate our results so far and the reasons we remain confident about the business. In the U.S. alone, the TULSA total addressable market amounts to 600,000 patients annually — a large figure, and one exceeding that of almost every competing technology. Physicians seek tools usable across many kinds of patients, rather than only within a slim segment of men dealing with prostate cancer and/or BPH.
Arun Menawat
executiveAt this point, some physicians have stopped using any other technology altogether and rely solely on TULSA for every one of their patients. We don't anticipate that all urologists will follow suit, but these early adopters show what TULSA can do. Our gross margin already sits above 70%. As the installed base keeps expanding, we expect recurring revenue from per-patient use of our disposables to eventually become the dominant share of our revenues. That said, reaching that enviable position requires capital sales to build up the TULSA installed base. Our internal analysis also shows our gross margin running at least 10% points above our competitors' margins, while the upfront capital cost of our technology runs roughly 20% to 50% lower. That mix, in our view, gives Profound and the customers we serve a compelling and distinctive economic offering. In January 2025, CMS approved a higher Level 7 reimbursement via the TULSA Procedure, and during the past year our revenues increased by roughly 50%. Looking at our full-year guidance for 2026, we anticipate growing no less than 55% in the current year. More concrete information regarding what to expect for 2027 growth targets will be shared early next year. For now, however, I can tell you that we are happy with the trajectory of growth that lies ahead, and our confidence in success has only grown following the signing of the new agreements with Telix and Cook. The point we want investors to take away about how much leverage our business model offers is just as straightforward. At this early stage, we're already putting less than $0.65 into sales and marketing to bring in each dollar of revenue. In contrast, our internal benchmarking shows that most of our peers generally lay out more than $1 to bring in $1 of revenue. We got here having invested under $300 million in total, while our internal benchmarking suggests relevant competitors typically invest over $1 billion; in our view, this mix of capital efficiency, gross margins, a recurring revenue business model and market breadth is the formula for building a profitable growth business. Going forward, standardization is essential to getting better use out of AI. TULSA already relies on standardized MR images, and surgeons already carry out the procedure while seated comfortably before a computer monitor rather than at an operating table. Combining those two elements, we think TULSA is the technology best positioned to keep expanding as AI becomes more widespread and interest grows in new concepts, telesurgery among them. To our customers, what we convey is that this is not merely a product sale. We are assisting them in moving toward the future of image-guided incisionless care, with support provided as they build proficiency. Even though the hurdles to establishing this platform have been rather high, we believe our message is connecting because it is logical and supported by clinical data. Having spent over ten years with Profound, I see the difficulties that lie ahead as largely matters of execution—ones we grasp and are equipped to handle. I don't minimize the scale of effort required, yet I have strong confidence in the expertise Rich contributes and in the way he, Tom and Matthew are already working together to steer the coming stage. The chance before us is considerable, and our position for pursuing it is solid. On the subject of the team, prior to opening the line for Q&A, I want to highlight the leadership news included in today's release. Rich will succeed me as Chief Executive Officer, taking effect January 14, 2027. Rich isn't just highly experienced at growing businesses — what draws me most is that he's very thoughtful, even-keeled and motivated from within by his own drive to succeed. Put differently, he is profound. Some of you may be surprised that I'm old enough for this change to land right on my 72nd birthday, but anyone who knows me will confirm that I still have a strong passion to see this through all the way. So I'll move into the Executive Chair role, supporting continuity and working alongside Rich and the team on strategy, Investor Relations and other priorities. We've also named Matthew Sobczyk as our permanent Chief Financial Officer. Matthew knows this business inside and out, since he joined Profound back in 2017, and he carries substantial expertise in financial strategy, reporting, treasury and capital markets transactions. He will be a key partner for us as we deploy resources and steer the company toward profitability. Finally, Jason Mills is joining our Board and takes over from Cynthia Lavoie. Jason's combination of MedTech strategy and capital markets know-how will prove valuable as we continue expanding. I'd also like to express my gratitude to Cynthia for her leadership and the contributions she made to Profound. In summary, Profound is breaking new ground with iMRI procedures built to enhance clinical confidence, procedural control and patient outcomes. Real-time MR guidance together with autonomous robotics deliver consistency and clarity throughout treatment planning, delivery and confirmation. When it comes to prostate cancer, we think we're moving past the early-adopter phase into the mainstream market by making TULSA a third, separate category — regional ablation. Doctors and patients are able to select whole-gland therapy, focal therapy, or any option in between. At the close of Q3 2026, the installed base for TULSA-PRO was 98. Our outlook for full-year revenue has risen from roughly $25 million to no less than that figure, and we still anticipate a full-year gross margin of 70% or above. Under the CMS final rule for 2027, which was released last evening, the premium Medicare pays for TULSA relative to rival technologies is growing across every treatment setting, including hospitals, ASCs and private physician practices. This becomes especially important once our TULSA+ initiative with Cook starts its rollout in 2027. Meanwhile, additional payers keep extending coverage to growing numbers of lives. To support long-term execution, we've put together a capable leadership group and Board, and our confidence remains that we're headed toward profitable growth. That wraps up our prepared remarks. We're glad to take your questions now. Operator?
Ben Haynor
analystFirst of all, speaking personally, it's clearly good to see CMS straighten things out when it comes to ASC reimbursement. I also picked up on the Cook announcement — you had them referring to additional sites of care; and then, on that same subject, TULSA+ is on schedule to secure FDA clearance. At the same time, you're stating that essentially every urologist wants control over their own MRI; so it looks like office-based labs and ASCs are going to turn out to be a pretty significant opportunity for you. Could you say a bit about how fast that could actually take shape? Is it a matter of early adopters needing to reach the full mainstream market? Or might it move faster than what you've witnessed with TULSA up to now?
Arun Menawat
executiveBen, thanks for asking. I hope I'm coming through clearly. Yes. I mean, I think the fact that CMS has issued a final rule committing that reimbursement in ASCs will be roughly 11,400 plus, which is approximately the same as what robotic surgery receives in the hospital setting. So I think the rationale for pursuing a TULSA+ program in ASCs is quite obvious and quite compelling. And I think, on the other end of the spectrum, I do believe ASCs are seeking out MRIs; and so I do think we'll find a fairly receptive audience. That said, we're only just beginning; so I'd say by the second half of next year, you'll start seeing the impact of this change.
Ben Haynor
analystDo you figure that's a thing you'll be in a position to tell us about, what that effect could look like, when you speak early next year regarding how you see 2027?
Arun Menawat
executiveYeah. What we're doing first, honestly, is collaborating with Cook to genuinely work out a strategy for entering that market. And then for sure, along the way, we'll keep you posted.
Ben Haynor
analystAll right, understood. Then I spotted — or perhaps I missed it — the Index 20 mentioned in the press release. Have you discontinued that, or what's the reasoning behind it? And how should people monitor our utilization progress going forward?
Arun Menawat
executiveYeah, we've discontinued that program. The thing is, we attempted to assemble something. But as Tom said, our — we've expanded to 98 sites at this point. We will definitely exceed 100 before this year ends. So the 20 Index had somewhat lost the purpose it originally served. We believe we're going to expand at a far more defined pace going forward. And you're going to — you saw we've treated 5,000 patients. Usage keeps rising. So I just think that was more a matter of early-stage thinking. At this point we're thinking more along the lines of a growth environment, and it simply makes sense to try something. And if it didn't pan out, then let's just move on.
Ben Haynor
analystAll right, that's fair. And finally, perhaps a question for Matthew. I saw that receivables rose rather modestly given the big jump in sales. Looking ahead, how do you expect cash collections to track as sales ramp up?
Matthew Sobczyk
executiveThanks for asking. Yes. As we keep growing, we're putting more emphasis on managing working capital and on converting our accounts receivable into cash promptly; so we're taking a proactive approach to collections, which includes, first, greater visibility and analysis into our outstanding receivables; second, regular conversations with customers; and third, increased accountability around collections time line. So we're trying to improve the consistency and predictability of the cash collections while also continuing to support our customers and ultimately, the growth of our business.
Ben Haynor
analystRich, Matthew, congratulations on the new role — and Arun, on the retirement that's coming up.
Michael Freeman
analystI'll pick up right where Ben left off. Arun, congratulations on how far you've taken this company. Watching it has truly been a pleasure. And congratulations to Rich for stepping into the top job here, and to Matthew on the permanent appointment. Yes. I think my first question is probably for Rich. What operational and commercial changes would you expect us to see over the next 12 months as you work to scale the company? And what do you see as the main constraints on scaling and gaining market share from here?
Richard Fabian
executiveYes. Thanks, Michael. Looking at where we are, it's a really interesting moment — we've made tremendous progress, and Q3 was quite strong. As we look at Q4 and beyond, we know we need to keep focusing on commercial excellence. Tom talked about a strong funnel and how we convert that into sales; but beyond that comes a greater emphasis on helping our customers grow procedure volume and utilization. And I'd say the — I don't want to call it final, because a lot of continued work goes into growing and scaling an organization like this; but the back-end operational efficiencies across operations and supply chain, making sure we're set for the growth we see, ensuring every order is fulfilled smoothly and execution on the operational front holds up — that's also going to be a high priority for us going forward.
Michael Freeman
analystOkay. Okay. So given that the TULSA 20, or the Index 20, has been retired, and I realize things can shift, I suppose the question is about scale, or at a large scale. Could you maybe share some thoughts on how utilization trended during the quarter?
Arun Menawat
executiveSure. I'd begin by saying that after a surgeon has tried TULSA, they're eager to do more of it. So the overall pattern is definitely that usage at our sites keeps climbing. As Rich more or less explained, the obstacles we encounter tend to involve logistics and planning — shifting away from treating a single patient at a time toward setting up TULSA Days. That's really where our objectives lie. Still, when you look at growth year-over-year, we're in that mid-double-digit range, same as last year. And so I believe — we believe that as we devote more focus to building out a bigger utilization team and customer support team, utilization will rise fairly quickly. Like I mentioned, it isn't the clinical data, and it isn't reimbursement; the real issue is assisting them with logistics and workflows so they can reach the point they're aiming for.
Michael Freeman
analystOkay, great. My final question concerns the Telix agreement. I'd like to hear how working with that company — pairing PSMA-PET with MRI, and with TULSA — might affect or grow your business, maybe serving as a route to expand the market. And if you could talk about how practical it is to bring all these modalities together, that would be useful for everyone here.
Arun Menawat
executiveSure, of course. As you know — as we've discussed previously, prostate cancer begins as a multifocal disease. So when PSMA-PET is used, it can show several spots within the prostate where cancer is present. That, I believe, is one very particular and important reason this partnership makes sense. As urologists visualize more of that cancer, we expect the ideal target for treating the prostate will fall somewhere between 75% and 95% of the gland. And once that approach gains wider acceptance, we believe TULSA will be the appropriate modality for treating the vast majority of patients. That aligns with our long-standing theme that MR is in fact the superior platform for intervention. Absolutely, it's the main platform for diagnosis, but it's also a better platform on the therapeutic side. By adding this and being able to demonstrate multifocal disease more effectively, we believe it will bring in more patients who then become eligible for TULSA. That is definitely the clinical objective. But the other point we mentioned in the presentation is that they have a sizable sales force and they know how to educate. So by tapping into that team, we think we can accomplish more than simply attempting to handle everything on our own.
Kyle Bauser
analystWell done on the management and Board transitions. Let me ask a follow-up about the Cook Medical partnership. From what you said, the material contribution seems to be timed for the second half of next year. Could you speak to the operating margins on that partnership? Of course a transfer price is involved, but lower OpEx on the capital sales, and certainly the recurring revenue stream, more than makes up for it. I'm simply hoping to understand how we ought to view margins in connection with that partnership.
Arun Menawat
executiveYes, Kyle, that's exactly the right frame. Considering the way things are set up, our expectation across the board is that gross margins will remain within the 70% to 75% band. With the distribution agreement as a whole, I believe that still holds, since Tom and Rich have mentioned that both the disposable business and the service business will be direct, which leaves things unchanged. So when you're modeling, I'd suggest keeping to the present assumption that our company's gross margins will land in that 70% to 75% range.
Kyle Bauser
analystUnderstood. Thanks for that. Perhaps we could discuss how SG&A balances operating efficiencies against growth. Matthew, do you have any view on the cadence of SG&A and how we ought to think about it across the coming few quarters?
Matthew Sobczyk
executiveAcross the coming few quarters, I'd say — once again, we'll be quite prudent and simply keep watching it. So right now, I'm not really in a position to offer any kind of trend we anticipate, but we will keep monitoring it and make sure we remain on top of it to the greatest extent we can. And, I suppose, concentrate on the overall business growth we need in order to hit our sales growth as well as the growth within the company.
Arun Menawat
executiveYes. And Kyle, what I'd add is that, as Tom mentioned, we still have a really big pipeline we're working through; and as Rich settles further into his new position, you're going to see us expand the business. So there will be fluctuations from quarter to quarter as we bring on people, and efficiency may not look as strong in any given quarter. But I think across 6-month or 12-month cycles, you'll keep seeing that we stay focused on efficiency, as Rich laid out — that's typical for companies growing in the 50% plus range: we're going to add people, and they won't be productive on day 1, but once they become productive, you'll begin to see efficiencies. So I'd expect some quarter-over-quarter fluctuation. Over the longer term, though, we're very focused on building not just a growth company but a profitable growth company.
Kyle Bauser
analystUnderstood. Thanks for the update. Yes, go ahead.
Richard Fabian
executiveKyle, this is Rich. I wanted to add to that point—we're going to keep a close eye on our expenses and stay prudent; but, as Arun just said, as we keep building and scaling toward our operational priorities, which include top line revenue and utilization, frequently when we bring on resources, the contribution trails by a couple of quarters, and we anticipate that. Still, we'll add in as responsible a way as we can as we scale up for the growth and for the market demand.
Blake Sommi
analystCongratulations on the quarter. I'm just wondering — to get a clearer sense of how utilization is pacing, do you have a specific reporting plan for the coming few quarters? I get that with Index 20 you don't think it matches a bigger installed base; but when it comes to decisions around this new system, will you have more visibility than the 2 quarters we saw with Index 20?
Arun Menawat
executiveYes, quite a lot; and one thing — Rich, by all means jump in on this. The point is, I believe, as you've already heard from Rich, he's an outstanding operator. He brings plenty of experience building businesses with very large revenues. And so I think what you're seeing right now is a company that's been in the market — what I call crossing the chasm — as we've gone back and forth, we've tried a number of things, right? And so we're now moving into that phase where the pipeline is far more reliable and utilization is getting more reliable. So I think Rich brings a lot of experience. And you'll see us gaining — building a much stronger ability to give you a consistent metric on utilization. But I just felt like this is also the right moment. If something didn't work, then let's just change it. And I think you'll see Rich develop new metrics and absolutely, we'll share it. Rich, by all means jump in.
Richard Fabian
executiveYes, I would agree with that. And Blake, I appreciate the question. This is a topic we consider every day — arguably every hour — specifically, what is the most effective approach for obtaining data from sites that are operational? As you're aware, even at the moment we first go live with a site, we have to get those sites operational and generating results. And as we bring on additional resources focused on utilization, how do we move a customer performing 1 case per week up to 2, and those at 2 up to 4, assisting them with scheduling and prioritization in every respect? And then there's also, I believe, the Cook piece of this, where you have dedicated iMRIs, which provides further evidence of the MRI's worth in procedural MRI. The following step will be to determine where and how that reporting cadence should look, and to remain transparent with our investment community.
Scott McAuley
analystRich and Arun, congratulations. My question concerns systems that have been sold but not yet installed. I believe there was some commentary in earlier quarters about a fairly significant lag with systems that may be sold but take a while to get installed; and the 98 systems that are installed is fantastic. Are there systems that have been sold but not installed yet? And are you seeing that time line shorten from a sale to getting them up and treating the patient?
Arun Menawat
executiveYes. Tom, please feel free to...
Thomas Tamberrino
executiveAbsolutely, glad to jump in on that. Thanks a lot for asking. Arun, I'll take it from here. We're definitely compressing the window between when a system is ordered and when it gets installed. As Rich mentioned earlier in his remarks regarding operational efficiencies, much of that stems from our organization maturing and from the fact that we're getting additional practice at it, more sequentially each quarter, driven by higher system sales. So with every repetition, we get more efficient — not just with delivery, installation, training, and launch, but also patient selection, treatment coordination, and follow-up on the procedure, and so forth. And you can understand that doing this worldwide brings some nuances to what I just described, particularly when we're launching first in country — we had several systems going first in country during Q3 of this year, with more to come in the quarter we're in now, and we're excited about our global expansion. As we mature, and as Arun alluded to, we look forward to sharing more detail specifically on procedural growth, same-store growth, and similar metrics. But where we are at present in terms of crossing the chasm — right — we're still comparatively light on the top line revenue tied to procedural growth, though the team we're building out will be sharply focused on that, and we'll have a group of program development managers whose only job is to do precisely what everyone is looking for, which is to drive procedural volume. The great news there is that the large majority of institutions around the world are motivated to do the same, so it's a genuine partnership in launching the TULSA program, growing the TULSA program, and then carrying on from there. We've got plenty of excitement about potential telesurgery procedures to create ubiquity of access to TULSA and TULSA Procedures across the world. So lots of great things ahead. Those are more comments and forward-looking projections, but it's all underway, and we're excited about this quarter and '27 and beyond.
Scott McAuley
analystThat's great. Maybe just to clarify something. I believe you said in there that some of these installations were the first of their kind in the country. As for the 98 current installed base, does that figure cover only the U.S.? Or is it a global number?
Thomas Tamberrino
executiveThat number is global.
Arun Menawat
executiveThat's worldwide, worldwide. Yeah.
Scott McAuley
analystCan you say, though, what share of that — or how many — is specifically based in the U.S.?
Arun Menawat
executiveThe large bulk, I'd put it, broadly, at a 70 to 30 ratio, and that's likely where it stays.
Scott McAuley
analystThat's excellent. So perhaps a bit of background on the pipeline would help. It's encouraging to see. I believe it stood at just above $70 million in the prior quarter, and now it's nearer $80 million across those later stages — Verify, Negotiate, and Contracting. Is that mostly reflecting the capital tied to the pipeline, meaning the capital equipment? Or does some portion of that dollar amount also capture an estimate of initial consumable usage?
Thomas Tamberrino
executiveReally good question, and I'd like to tease apart a few separate threads when it comes to the pipeline itself. Systems make up the vast majority of that pipeline. Within those system sales, though, we typically bundle in some initial consumable orders alongside each system sale. So a modest slice of revenue is folded into that $79.2 million figure we mentioned earlier on this call. What I find most exciting is that, after we shifted from a placement model to a capital model following the January 1, 2025, Medicare coverage for the TULSA procedure, we're now approaching the stage where service agreements will bring in added revenue; and the upside there is enormous, since we're all familiar with capital equipment and the agreements that come with it, whether that's for MRI machines or other capital assets. So in brief, the answer is that it's mostly capital. A small amount is consumables, and service sits outside of that as well; so we'll be positioned to generate multiple revenue streams — capital, consumables, service, software, clinical case coverage, and so on — and we're getting to the point where we can monetize the whole operation, built on the success we've had with the TACT study, the CAPTAIN study, and now what I'd call real-world results from independent physicians, which we keep seeing as abstracts, poster presentations, and peer-reviewed journal publications around the world, with real-world experience matching, if not exceeding, what our own sponsored studies have shown.
Scott McAuley
analystThat's wonderful. That's excellent. And finally, regarding insurance coverage, it's really good to see roughly 11 million more lives covered — just under 11 additional million. Do you know the total figure, kind of as of today or at the quarter's end, for lives covered either via commercial payers or commercial plus government payers combined?
Thomas Tamberrino
executiveApologies for that. I was muted as I came off it. Arun, would you like to take it, or would you prefer that I do?
Arun Menawat
executiveNo, no. No, you go ahead, please.
Thomas Tamberrino
executiveYes. So the thing I wanted to bring up there is that a total figure hasn't been given by us. Quarterly updates are what we've been offering; and part of that approach is that we want to reach a point where very specific details can be shared regarding particular insurers, especially the bigger organizations, which naturally require time to reach. But at least 10 million per quarter is what we're adding. And if you were to ask me for a total figure, I would say to you at this moment that it stands at somewhere between 35 million and 40 million covered lives from when our health economics and market access work began; but the key push I really want to emphasize is that the CAPTAIN results, which are expected to be presented at the 1-year mark at RSNA by Dr. Ghanouni from Stanford on that first Monday, will hand us extra ammunition for dealing with policy writers and medical directors at insurance providers nationwide. So we're very enthusiastic about the success achieved so far, and it will only get stronger as the calendar turns with respect to the CAPTAIN study.
Scott McAuley
analystAbsolutely, we're really looking forward to that.
Arun Menawat
executiveIs there anything else anyone wants to ask? Any further questions? Alright then.
Stephen Kilmer
executiveApologies, Arun — Steve speaking. I believe the operator ran into some kind of issue. So please go right ahead, and there was one additional questioner. We'll bring him back on. Sorry about that.
Arun Menawat
executiveAlright, Rich will be taking charge of all upcoming analyst calls. That means it'll happen starting next year. I also want to express my gratitude to our investor base — and especially to the analysts — for their backing throughout the past several years; Rich, Tom, and Matthew will keep leading the way and will seek out a growth company as we move ahead. Thanks so much. Enjoy your evening.
Richard Fabian
executiveThank you.
Operator
operatorThank you. This does conclude our program for today. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Profound Medical Corp. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Profound Medical Corp. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Profound Medical Corp. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.